Primagen receives 'notice of allowance' for Mitox patent
Dutch company Primagen Holding, a provider of molecular diagnostics tests for infectious diseases, AIDS and cancer, has received a 'notice of allowance' from the US Patent and Trademark Office for the use of mitochondrial nucleic acid as a tool to measure toxicity and efficacy of pharmaceutical compounds.
Dutch company Primagen Holding, a provider of molecular diagnostics tests for infectious diseases, AIDS and cancer, has received a 'notice of allowance' from the US Patent and Trademark Office for the use of mitochondrial nucleic acid as a tool to measure toxicity and efficacy of pharmaceutical compounds.
Mitochondrial Toxicity assessment is an integral part of Primagen's plans to introduce a broad array of Mitox applications that can be used to manage and treat disease.
The notice of allowance indicates that the company has fulfilled all requirements for the issuance of a new patent entitled 'Method of determining therapeutic activity and/or possible side-effects of a medicament', which is expected to be issued in the next two to three months. Its proprietary mitochondrial nucleic acid marker technology enables researchers and clinicians to measure mitochondrial nucleic acid levels with a simple, real-time molecular diagnostics test.
'This is the first patent allowance for our family of Mitox applications that were filed worldwide, and we strongly believe that allowances in other key markets will follow soon,' said Bob van Gemen, ceo of Primagen Holding. 'Our Mitox products are currently used in the US and Europe, with additional market expansion planned for 2005 in the Far East, Australia and Latin America.'